A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 555
- 试验地点
- 279
- 主要终点
- Progression free survival (PFS) per RECIST 1.1 as assessed by BICR
研究概览
简要总结
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer that has spread nearby or to other parts of the body or is unlikely to be controlled with current treatments. HER2 is a protein that helps cells to grow and divide. Sometimes, cancer cells have a damaged HER2 gene. This is called a mutation. This mutation can lead to an abnormal HER2 protein which may cause cancer cells to grow and divide too quickly.
The study treatment, sevabertinib, is designed to block the mutated HER2 protein and may help slow or stop the cancer from growing.
The main purpose of this study is to find out how well sevabertinib works and how safe it is, compared with standard treatment in participants with advanced NSCLC with a HER2 mutation.
The study participants will receive one of the study treatments:
- Sevabertinib as a tablet taken by mouth twice a day
- Standard approved treatment for this condition given by infusion into a vein every 21 days Participants will continue their assigned treatment for as long as they benefit from it and do not experience severe side effects, or until they or their doctor decide to stop treatment. When a participant assigned to the standard treatment has their cancer gets worse, they may have the opportunity to switch to receive sevabertinib. This switch is called a crossover.
Participants who switch to sevabertinib will continue this treatment until their disease gets worse again, they have side effects that are too severe, or they or their doctor decide to stop treatment.
During the study, the research team will:
- do scans such as CT, PET, MRI, or X-rays to check the cancer
- Check the overall health of the participants by performing tests such as blood and urine tests and checking heart health using an electrocardiogram and echocardiogram.
- do pregnancy tests when needed
- ask how the participants are feeling and whether they have had any adverse events or other health problems An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signing the informed consent.
- •Documented histologically or cytologically confirmed locally advanced non-squamous NSCLC, not suitable for definitive therapy or metastatic non-squamous NSCLC at screening (small cell or mixed histologies are excluded) (Stage III-IV NSCLC).
- •Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified (US sites) or an equally accredited (outside of the US) local laboratory. However, participants may be included at the discretion of the investigator if the laboratory performing the assay is not CLIA or similar certified but the laboratory is locally accredited.
- •No prior systemic therapy for locally advanced or metastatic disease. No prior treatment with a HER2 ex20ins-targeted therapy (e.g. poziotinib, trastuzumab deruxtecan). Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of screening.
- •Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the SmPC/Product Information.
排除标准
- •Known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy. Exception: the following cancer types are acceptable within five years if curatively treated or under surveillance:
- •a. in situ cancers of cervix, breast, or skin,
- •b. superficial bladder cancer (Ta, Tis and T1),
- •c. limited-stage prostate cancer,
- •d. basal or squamous cancers of the skin.
- •Tumors with targetable alterations with approved available therapy, with the exception of HER2 mutation in the TKD.
- •Inability to discontinue treatment with chronic systemic corticosteroids. Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for >4 weeks prior to planned start of study intervention.
- •Pre-existing peripheral neuropathy that is Grade ≥2 by CTCAE (v5.0).
- •History of severe hypersensitivity reaction to treatment with a monoclonal antibody.
- •Prior radiotherapy outside of the brain within 21 days before of planned start of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.
研究组 & 干预措施
Standard of care (SoC)
Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria. Participants in the SoC arm will have the opportunity to crossover to receive sevabertinib when they experience disease progression.
干预措施: Pemetrexed (Drug)
Standard of care (SoC)
Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria. Participants in the SoC arm will have the opportunity to crossover to receive sevabertinib when they experience disease progression.
干预措施: Carboplatin (Drug)
Standard of care (SoC)
Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria. Participants in the SoC arm will have the opportunity to crossover to receive sevabertinib when they experience disease progression.
干预措施: Pembrolizumab (Drug)
Standard of care (SoC)
Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria. Participants in the SoC arm will have the opportunity to crossover to receive sevabertinib when they experience disease progression.
干预措施: Cisplatin (Drug)
Sevabertinib
Participants will receive sevarbetinib 20 mg BID until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
干预措施: Sevabertinib (Drug)
结局指标
主要结局
Progression free survival (PFS) per RECIST 1.1 as assessed by BICR
时间窗: Up to approximately 2 years
RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR)
次要结局
- Overall survival (OS)(Up to approximately 4 years.)
- Objective response rate (ORR) per RECIST 1.1 as assessed by BICR(Up to approximately 4 years)
- Progression free survival (PFS) per RECIST 1.1 as assessed by the investigator(Up to approximately 4 years)
- Objective Response Rate (ORR) per RECIST 1.1 as assessed by the investigator(Up to approximately 4 years)
- Disease control rate (DCR) per RECIST 1.1 as assessed by BICR(Up to approximately 4 years)
- Disease control rate (DCR) per RECIST 1.1 as assessed by the investigator(Up to approximately 4 years)
- Duration of response (DOR) as assessed by BICR(Up to approximately 4 years)
- Duration of response (DOR) as assessed by the investigator(Up to approximately 4 years)
- Adverse events per CTCAE v 5.0 (eg. TEAEs, TESAEs) categorized by severity(Up to approximately 4 years)
- Change from baseline in NSCLC-SAQ total score(Up to approximately 4 years)
- Change from baseline in NSCLC-SAQ individual domain scores(Up to approximately 4 years)
- Time to deterioration in NSCLC-SAQ total score(Up to approximately 4 years)
- Time to deterioration in NSCLC-SAQ individual domain scores(Up to approximately 4 years)
- Time to deterioration in EORTC QLQ-C30 physical functioning domain score(Up to approximately 4 years)
- Change from baseline in EORTC QLQ-C30 physical functioning domain score(Up to approximately 4 years)
- Change from baseline in EORTC QLQ-C30 global health status/QoL(Up to approximately 4 years)